1. Pardridge, W. M. (1991). Advances in cell biology of blood-brain barrier transport. Semin Cell Biol 2, 419-426.

2. Engelhard, H. H. (2000). Brain tumors and the blood-brain barrier. In Neuro-Oncology: The Essentials (M. Bernstein, and M. Berger, Eds.), pp. 49-53, Thieme, New York.

3. Barshes, N., Demopoulos, A., and Engelhard, H. H. (2005). Anatomy and physiology of the leptomeninges and CSF space. In Leptomeningeal Cancer (L. Abrey, M. C. Chamberlain, and H. H. Engelhard, Eds.), Norwell, Kluwer Academic Publishers, Massachusetts.

4. Nabeshima, S., Reese, T. S., Landis, D. M. D., and Brightman, M. W. (1975). Junctions in the meninges and marginal glia. J Comp Neur 164, 127-134.

5. Zinke, H., Mockel, B., Frey, A., Weiler-Guttler, H., Meckelein, B., and Gassen, H. G. (1992). Blood-brain Barrier: A molecular approach to its structural and functional characterization. In Progress in Brain Research 91 (A. Ermisch, R. Landgraf, and H. J. Ruhle, Eds.), pp. 103-116, Elsevier Science Publishers.

6. Greig, N. H. (1989). Brain tumors and the blood-tumor barrier. In Implications of the Blood-brain Barrier and Its Manipulation (E. A. Neuwelt, Ed.), Vol. 2. pp 77-106. Plenum Medical Book Co. New York.

7. Engelhard, H. H., and Groothuis, D. G. (1998). The blood-brain barrier: Structure, function and response to neoplasia. In The Gliomas (M. Berger, and C. Wilson, Eds.), pp. 115-121. W. B. Saunders Co., Philadelphia.

8. DeBoer, A. G., and Breimer, D. D. (1994). The blood-brain barrier: Clinical implications for drug delivery to the brain. J Royal College Physicians London 28, 502-506.

9. Neuwelt, E. A. (2004). Mechanisms of disease: the blood-brain barrier. Neurosurgery 54, 141-2.

10. Abbott, N. J., Revest, P. A., and Romero, I. A. (1992). Astrocyte-endothelial interaction: physiology and pathology. Neuropath Appl Neurobiol 18, 424-433.

11. Abbott, N. J. (2005). Dynamics of CNS barriers: Evolution, differentiation, and modulation. Cell Mol Neurobiol 25, 5-23.

12. Wolburg, H., and Lippoldt, A. (2002). Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 38, 323-337.

13. Vorbrodt, A. W., and Dobrogowska, D. H. (2003). Molecular anatomy of intercellular junctions in brain endothelial and epithelial barriers: electron microscopist's view. Brain Res Brain Res Rev 42, 221-42.

14. Risau, W. (1994). Molecular biology of blood-brain barrier ontogenesis and function. Acta Neurochir (Wien) 60 Suppl 109-112.

15. DeVries, H. E., Montagne, L., Dijkstra, C. D., van der Valk, P. (2004). Molecular and cellular biology of the blood-brain barrier and its characteristics in brain tumors. In Contemporary Cancer Research: Brain Tumors (F. Ali-Osman. Ed.), pp. 157-174, Humana Press, New Jersey, Totowa.

16. Milhorat, T. H. (1975). The third circulation revisited. J Neurosurg 42, 628-645.

17. Prieto, M., Chauvet, N., and Alonso, G. (2000). Tanycytes transplanted into the adult rat spinal cord support the regeneration of lesioned axons. Exp Neurol 161, 27-37.

18. Pardridge, W. M. (1986). Blood-brain barrier transport of nutrients. Fed Proc 45, 2047-9.

19. Salcman, M., and Broadwell, R. D. (1991). The blood-brain barrier. In Neurobiology of Brain Tumors (M. Salcman, Ed.), pp. 229-249. Williams & Wilkins. Baltimore.

20. Allen, D. D., and Lockman, P. R. (2003). The blood-brain barrier choline transporter as a brain drug delivery vector. Life Sci 73, 1609-15.

21. Graff, C. L., and Pollack, G. M. (2004). Drug transport at the blood-brain barrier and the choroid plexus. Cur Drug Metab 5, 95-108.

22. Shah, G. N., and Mooradian, A. D. (1997). Age-related changes in the blood-brain barrier. Experimental Gerontology 32, 501-19.

23. Sun, H., Dai, H., Shaik, N., and Elmquist, W. F. (2003). Drug efflux transporters in the CNS. Adv Drug Deliv Rev 55, 83-105.

24. Regina, A., Demeule, M., Laplante, A. et al. (2001). Multidrug resistance in brain tumors: roles of the blood-brain barrier. Cancer Metastasis Rev 20, 13-25.

25. Bart, J., Groen, H. J., Hendrikse, N. H. et al. (2000). The blood-brain barrier and oncology: New insights into function and modulation. Cancer Treat Rev 26, 449-62.

26. Hosoya, K., Ohtsuki, S., and Terasaki, T. (2002). Recent advances in the brain-to-blood efflux transport across the blood-brain barrier. Int J Pharm 248, 15-29.

27. Fishman, R. A. (1992). Cerebrospinal Fluid in Diseases of the Nervous System. W.B.Saunders Co., Philadelphia.

28. Van Vulpen, M., Kal, H. B., Taphoorn, M. J., El-Sharouni, S. Y. (2002). Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? Oncol Rep 9, 683-8.

29. Fortin, D. (2004). The blood-brain barrier should not be underestimated in neuro-oncology. Revue Neurologique 160, 523-32.

30. Kroll, R. A., and Neuwelt, E. A. (1998). Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42, 1083-99.

31. Waterhouse, R. N. (2003). Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 5, 376-89.

32. Engelhard, H. H., Duncan, H., Kim, S., Criswell, P. S., and Van Eldik, L. (2001) Therapeutic effects of sodium butyrate on glioma cells in vitro and in the rat C6 glioma model. Neurosurgery 48, 616-625.

33. Groothuis, D. R. (2000). The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery. Neuro-oncol 2, 45-59.

34. Golden, P. L., and Pollack, G. M. (2003). Blood-brain barrier efflux transport. J Pharm Sci 92, 1739-53.

35. Sun, H., Dai, H., Shaik, N., and Elmquist, W. F. (2003). Drug efflux transporters in the CNS. Adv Drug Deliv Rev 55, 83-105.

36. Kemper, E. M., Boogerd, W., Thuis, et al. (2004). Modulation of the blood-brain barrier in oncology: Therapeutic opportunities for the treatment of brain tumors? Cancer Treat Rev 30, 415-23.

37. Grabb, P. A., and Gilbert, M. R. (1995). Neoplastic and pharmacological influence on the permeability of an in vitro blood-brain barrier. J Neurosurg 82, 1053-58.

38. Gratton, J. A., Abraham, M. H., Bradbury, M. W., and Chadha, H. S. (1997). Molecular factors influencing drug transfer across the blood-brain barrier. J Pharm Pharmacol 49, 1211-6.

39. Chakrabarty, S. P., and Hanson, F. B. (2005). Optimal Control of Drug Delivery to Brain Tumors for a Distributed Parameters Model. Proceedings of 2005 American Control Conference, pp. 1-6.

40. Dash, A. K., and Elmquist, W. F. (2003). Separation methods that are capable of revealing blood-brain barrier permeability. J Chromatogr B Analyt Technol in the Biomed Life Sci 797, 241-54.

41. DeAngelis, L. M. (2003). Benefits of adjuvant chemotherapy in high-grade gliomas. Semin Oncol 30 (6 Suppl 19), 15-18.

42. Schiffer, D. (1993). Brain Tumors: Pathology and its Biological Correlates. Springer-Verlag, New York.

43. Giese, A., and Westphal, M. (1996). Glioma invasion in the central nervous system. Neurosurgery 39, 235-250.

44. Rapoport, S. I. (2001). Advances in osmotic opening of the blood-brain barrier to enhance CNS chemotherapy. Expert Opin on Investing Drugs 10, 1809-18.

45. Zunkuler, B., Carson, R. E., Olson, J. et al. (1996). Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg 85, 1056-65.

46. Doolittle, N. D., Miner, M. E., Hall, W. A. et al. (2000). Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88, 637-47.

47. Cloughesy, T. F., and Black, K. L. (1995). Pharmacological blood-brain barrier modification for selective drug delivery. J Neurooncol 26, 125-32.

48. Dahlborg, S. A., Henner, W. D., Crossen, J. R. et al. (1996). Non-AIDS primary CNS lymphoma: First example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am 2, 166.

49. Park, D. M., and Abrey, L. E. (2002). Pharmacotherapy of primary CNS lymphoma. Expert Opin Pharmacother 3, 39-49.

50. Plotkin, S. R., and Batchelor, T. T. (2002). Primary central nervous system lymphoma. Curr Treatment Options Oncol 3, 525-35.

51. Engelhard, H. (2000). The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg Neurol 53, 458-464.

52. Dunn, I. F., and Black, P. M. (2003). The neurosurgeon as local oncologist: cellular and molecular neurosurgery in malignant glioma therapy. Neurosurgery 52, 1411-22.

53. Blomer, U., Ganser, A., and Scherr, M. (2002). Invasive drug delivery. Adv Exp Med Biol 513, 431-51.

54. Bansal, K., and Engelhard, H. H. (2000) Gene therapy for brain tumors. Cur Oncol Rep 2, 463-472.

55. Engelhard, H. H., Egli, M., and Rozental, J. (1998) Use of antisense vectors and oligodeoxynucleotides in neuro-oncology. Pediatr Neurosurg 29, 1-10.

PLATE 15.1 (Fig. 15.1)
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment